bpc-157 fda warning letter compounding issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of fda warning letter bpc-157 unapproved

(CSE: BPC) (OTCQB: PNGAF) announced on July 14, 2026, that it has received its full production run of approximately 20,000 units of its BPC-157 transdermal patch, the company's lead product candidate

Your physician will evaluate your condition, answer questions about how to get BPC-157 for recovery, and send your prescription directly to your preferred pharmacy if approved

A lot/batch identifier is recorded on the product label where available and corresponds to the COA shown on this page

BPC-157 vs TB-500: Comprehensive Comparison of Recovery and Healing Peptides for Research BPC-157 and TB-500 are two peptides extensively studied in preclinical research for their potential influence on tissue repair processes, with complementary but distinct mechanisms